Benefits
Supports lumbar spine bone density
In a 12-month randomized, double-blind, placebo-controlled trial (131 enrolled, 102 completed), 5 g/day of specific collagen peptides changed the lumbar spine T-score by +0.1 (SD 0.26) versus -0.03 (SD 0.18) in the control group, p=0.030. The change is small relative to its own spread. Bone mineral density is a surrogate: the trial measured DXA scores, not fractures, and the paper describes the tested material as specific collagen peptides rather than by the FORTIBONE® brand name.
Supports femoral neck bone density
In the same 12-month trial, the femoral neck T-score changed by +0.09 (SD 0.24) with 5 g/day of specific collagen peptides versus -0.01 (SD 0.19) in the control group, p=0.003. This was a densitometry outcome only. No fall or fracture outcome was measured, so the result should not be read as a change in fracture risk.
Mixed effects on bone turnover markers
The marker results do not all point one way. In the 2020 randomized trial that added specific collagen peptides to calcium and vitamin D in postmenopausal women with osteopenia, the bone formation marker P1NP fell by 13.1% (p<0.001) and the bone breakdown marker CTX fell by 11.4%, which did not reach statistical significance (p=0.058); the calcium and vitamin D only group showed no significant change in either marker. The 2018 density trial also reported bone marker changes. Turnover markers are laboratory measures and do not by themselves show a change in bone strength.
Easy daily addition for women's bone routine
FORTIBONE® dissolves easily in water, coffee, or smoothies and is essentially tasteless, so it is easy to take alongside calcium and vitamin D. This is a note on formulation convenience, not clinical evidence: no cited study tested taste, mixing, or adherence.
Tolerability reported over 12 months
The 12-month trial reported no serious adverse events at 5 g/day in postmenopausal women. Note that 131 women enrolled and 102 completed, so the tolerability picture comes from a single trial with substantial attrition, and the tested material was described as specific collagen peptides rather than by brand.
Mechanism of action
Osteoblast stimulation by collagen peptides
Specific bioactive peptides in FORTIBONE® are absorbed and may reach bone tissue, where they can signal osteoblasts to increase synthesis of type I collagen, the main organic component of the bone matrix on which mineralization occurs.
Substrate supply for bone matrix
Collagen peptides provide glycine, proline, and hydroxyproline in the high concentrations needed for de novo synthesis of bone collagen, complementing minerals such as calcium and phosphate that build the mineral phase.
Optimized peptide profile
Gelita's proprietary enzymatic hydrolysis yields a defined peptide spectrum (~3-5 kDa) intended to maximize delivery of bioactive fragments relevant to bone cells, differentiating FORTIBONE® from non-specific collagen hydrolysates.
Modulation of bone turnover markers
Serum markers of bone formation and resorption did change in the cited trials, but not consistently in the direction this mechanism predicts. In the 2020 trial the formation marker P1NP fell 13.1% and the resorption marker CTX fell 11.4% without reaching significance (p=0.058). This remains a proposed explanation rather than a demonstrated one.
Clinical trials
Randomized, double-blind, placebo-controlled trial; 12 months; 5 g/day of specific collagen peptides. Nutrients 2018, PMID 29337906. The brand name FORTIBONE® does not appear in the published paper.
131 postmenopausal women with reduced (primary) BMD at the lumbar spine or femoral neck were enrolled; 102 completed the 12 months.
Over 12 months the lumbar spine T-score changed by +0.1 (SD 0.26) versus -0.03 (SD 0.18) with placebo (p=0.030), and the femoral neck T-score by +0.09 (SD 0.24) versus -0.01 (SD 0.19) (p=0.003). Both changes are small relative to their standard deviations. BMD is a surrogate measure and no fracture outcome was recorded.
Randomized trial of calcium and vitamin D with or without specific collagen peptides; bone turnover markers assessed. J Musculoskelet Neuronal Interact 2020, PMID 32131366.
Postmenopausal women with osteopenia.
In the collagen peptide group the bone formation marker P1NP fell 13.1% (p<0.001) and the bone breakdown marker CTX fell 11.4%, which did not reach statistical significance (p=0.058). The calcium and vitamin D only group showed no significant change in either marker. These are laboratory markers of bone turnover, so this trial says nothing about bone density, fracture risk, or symptoms.